Identifying The Need Paediatric and geriatric patients usually
have difficulty in swallowing most types of solid dosage
forms and therefore drugs are administered to these
patients as liquid formulations. Such formulations,
however, pose issues of manufacture, stability, transportation,
and precision in measurement of the dose while administering.
A satisfactory means of achieving a liquid form for
use after reconstitution is highly desirable.
The Rubicon Research Solution
RubiDTTM
is a tablet that disintegrates rapidly in water to form
a homogeneous dispersion.
It incorporates a high viscosity polymer that dissolves
on disintegration leading to an increase in the viscosity
of the dispersion. This ensures an instant formation
of the suspension with reduced sedimentation rate. The
unique feature of RubiDTTM
is the rapid disintegration of the tablet despite the
presence of the high-viscosity polymer.
The
System Performance
Intellectual Property
The RubiDTTM
technology is covered by pending patent applications. Key Attributes of RubiDTTM
•
Versatile with respect to the category of the drug molecule
•
Suitable for relatively high dose actives
•
Excipients employed are traditional and pharmacopoeial
•
Conventional method of manufacture
•
Enhanced stability profile compared to liquid formulations Benefits
•
Rapid Onset of Action
•
Uniformity of dose
•
Good patient compliance
•
Reduction in variability of response
